57 results about "Inflammation Process" patented technology

The process of the invention relates to a kit of two cosmetic, pharmaceutical, veterinary and food compositions, designed for slimming or for preventing and/or repairing inflammatory mechanisms, one of the compositions comprising at least one sirtuin activator and at least one HSP activator, and the other composition comprising at least one sirtuin inhibitor and at least one HSP inhibitor.

The said compositions are intended to be delivered in a chronomodulated pattern. They are particularly effective in combination with one another for controlling fat tissues, adipose, fibrous or aqueous cellulite, cell aging and inflammatory processes.

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain and inflammation includes a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin1 antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin1 antagonist, a bradykinin2 antagonist and a mu -opioid agonist.

Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2:COX-1 activity inhibition is at least 3:1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro-alpha-methyl-9H-carbazole-2-acetic acid.

This invention relates to the use of a thylakoid extract that is preferably stabilized and activable for treating inflammation. Different types of cell or tissue targets and inflammatory stimuli have been used to evaluate the performance of the extract, which, in all cases successfully modulate inflammation through a balance of pro/anti-inflammatory cytokines. Compositions comprising the extract and other anti-inflammatory agents, namely glucocorticoids or NSAIDs are further disclosed and claimed.

Methods and compositions employing plaque associated molecules effective in inducing mucosal tolerance and inhibiting inflammatory processes contributing to atheromatous vascular disease and sequalae are provided.

The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.

Nutritional approaches for the control of inflammation can involve the administration of therapeutic amounts of calcium. The administration of appropriate amounts of calcium to an individual results in a reduction in inflammatory processes and markers associated with the inflammatory processes. The therapeutic amount of calcium can be selected to change a level of inflammation in the individual. The approach for reducing inflammation can comprise a step of measuring the C-reactive protein marker level and administering calcium in amounts selected to induce a change in the C-reactive protein level. The calcium can be incorporated into a product with corresponding instructions to induce a desired inflammation reduction.

The invention discloses an application of a small-molecular inhibitor MLN4924 in preparation of a drug for inhibiting bleomycin-induced pulmonary fibrosis. The invention also discloses an application of the small-molecular inhibitor MLN4924 in preparation of a drug for inhibiting an early inflammation process of bleomycin-induced pulmonary fibrosis. The invention also discloses an application of the small-molecular inhibitor MLN4924 in preparation of a drug for inhibiting activation of NF-[kappa]B and MAPK signal pathways in inflammatory reactions.

A method and solution for perioperatively inhibiting tumor cell adhesion and a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes at least one anti-tumor cell adhesion agent and multiple pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit tumor cell adhesion, pain and inflammation includes at least one anti-tumor cell adhesion agent, a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokininl antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykininl antagonist, a bradykinin2 antagonist and a mu -opioid agonist.

The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.

The invention discloses a testing test system for a spectrum in the high temperature stage of the spontaneous combustion inflammation process of coal. The system comprises a constant-temperature furnace, a coal sample tank, a constant-temperature furnace lifting mechanism, an air supply system and a temperature control cabinet; the constant-temperature furnace comprises a constant-temperature furnace body, a constant-temperature furnace cover, a furnace hearth and a heating unit; the coal sample tank is composed of a tank body and a tank cover, and a coal sample tank quartz glass observation hole is formed in the middle of the tank body; the constant-temperature furnace lifting mechanism comprises a support frame, lifters, a motor, shaft steering gears, first transmission shafts, second transmission shafts and lifting bases, and four guiding columns are installed on the support frame; the air supply system comprises an air source, a drying tube, a pressure stabilizing valve, a gas mass flow meter and a preheating tube. The invention further discloses a testing test system for the spectrum in the high temperature stage of the spontaneous combustion inflammation process of the coal. According to the system and method, design is novel and reasonable, implementation, usage and operation are convenient, temperature control is precise, the coal sample molecular structure change condition of the coal in the high-temperature spontaneous combustion condition can be truly reflected, the practicability is high, and usage and popularization are convenient.

The invention discloses a ureido-containing benzimidazole derivative, whose structural general formula is shown as a formula (I). The invention also discloses a preparation method of the compound and application of the compound in the preparation of medicines for resisting chronic kidney diseases. The derivative is an inhibitor of selective homologous domain interacting protein kinase-2 (HIPK2), can lower the protein level of the HIPK2 at the same time to play a dual role, has an inhibition effect on the HIPK2 kinase and protein level, a fibrosis signal molecule smad3 and an inflammation signal molecule I[kappa]B-alpha phosphorylation level, can adjust the fibrosis and inflammation processes at the same time, and has a good market application prospect as chronic kidney disease treatment medicines.

The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.